Table 2.
Carcinogenicity of estrogens, catechol estrogens, and quinones in B6C3F1 male mice
| Compound | Dose nmol/g body weight | Effective no. of animals | Total no. of tumors/TBA | TBA, % | Liver tumors
|
No. of mice with other neoplasms | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total no. of tumors/TBA | TBA, % | Carcinomas/TBA | TBA, % | Adenomas/TBA | TBA, % | ||||||
| E2 | 30 | 20 | 6/6 | 30 | 5/5 | 25 | 3/3 | 15 | 2/2 | 10 | 1A |
| 2-OHE2 | 30 | 28 | 13/10 | 36 | 10/9 | 32 | 5/4 | 14 | 5/5 | 18 | 1B, 1C, 1D |
| 4-OHE2 | 30 | 24 | 15/10 | 42 | 13/8 | 33 | 6/5 | 21 | 7/3 | 12 | 2A |
| E22,3-Q | 7.5 | 26 | 10/8 | 31 | 108 | 31 | 6/5 | 19 | 4/3 | 12 | |
| E2-3,4-Q | 7.5 | 21 | 5/4 | 19 | 5/4 | 19 | 4/3 | 14 | 1/1 | 5 | |
| E1 | 30 | 32 | 4/3 | 9 | 3/2 | 6* | 0 | 0† | 3/2 | 6 | 1A |
| 2-OHE1 | 30 | 30 | 11/9 | 30 | 9/7 | 23 | 4/4 | 13 | 5/4 | 13 | 1B, 1E |
| 4-OHE1 | 30 | 33 | 8/8 | 24 | 6/6 | 18 | 5/5 | 15 | 2/2 | 6 | 1A |
| E12,3-Q | 7.5 | 25 | 17/12 | 48 | 14/11 | 44 | 12/9 | 36 | 2/2 | 8 | 2A |
| E1-3,4-Q | 3.7 | 10 | 13/6 | 60 | 13/6 | 60‡ | 13/6 | 60§¶ | 0 | ||
| BP | 60 | 12 | 74/12 | 100 | 68/12 | 100 | 55/11 | 92 | 13/7 | 58 | 4B, 1F |
| Solvent | 19 | 11/7 | 37 | 9/5 | 26 | 5/4 | 21 | 4/2 | 10 | 2A | |
| Untreated | 33 | 11/11 | 33 | 8/8 | 24 | 6/6 | 18 | 2/2 | 6 | 3A | |
Effective number of animals, number of mice that survived after weaning; TBA, tumor-bearing animals; A, lung adenoma; B, lung carcinoma; C, eye papillary carcinoma (sebaceous); D, pancreatic lymph node lymphoma; E, spleen lymphoma; F, malignant lymphoma; BP, benzo[a]pyrene.
The mice treated with E1 had significantly fewer tumors than the untreated mice (P = 0.046).
E1 was significantly less carcinogenic than the solvent (P < 0.016) and no treatment (P < 0.013).
E1-3,4-Q was significantly more tumorigenic than no treatment (P < 0.044).
E1-3,4-Q was significantly more carcinogenic than the solvent (P < 0.047).
E1-3,4-Q vs. BP does not approach the nominal 0.05 P value of the level of significance.